Today: 1 May 2026
JPMorgan stock: what to watch as earnings kick off and CPI looms on Wall Street
13 January 2026
1 min read

JPMorgan stock: what to watch as earnings kick off and CPI looms on Wall Street

New York, January 13, 2026, 06:05 EST — Premarket

JPMorgan Chase shares edged up 0.6% in premarket trading as investors braced for the bank’s quarterly earnings and a U.S. inflation report that could shift rate expectations. Stock index futures dipped slightly, with S&P 500 e-minis down 0.14% in early action.

Why it matters now: JPMorgan is the first major U.S. bank to weigh in. Traders often use its remarks as an early gauge of deal activity, trading demand, and borrower sentiment in an economy that’s still firing on all cylinders.

This is also about rates. Bank earnings and valuations can shift quickly as the market recalibrates its view on the Federal Reserve’s next move, since lending margins and loan demand hinge on where interest rates are headed.

U.S. stocks wrapped up Monday at record highs, buoyed by strong tech shares and a 3% surge in Walmart. The day kicked off on edge after U.S. prosecutors launched a criminal probe into Fed Chair Jerome Powell, yet “the market is taking it in stride for now,” noted Peter Cardillo, chief market economist at Spartan Capital Securities. Reuters

Bank stocks stumbled after President Donald Trump proposed a one-year cap of 10% on credit-card interest rates, limiting what lenders can charge. JPMorgan dipped 2.5% early Monday, while Bank of America fell 1.6%, Reuters reported. UBS Global analysts said implementing such caps would require “an Act of Congress.” J.P. Morgan’s Vivek Juneja cautioned the move “could push consumers towards more expensive debt.” Reuters

A Reuters report highlighted Wall Street’s skepticism about a federal cap making it through Congress, pointing out that such a move requires legislation and a unilateral effort would probably be tied up in legal battles. TD Cowen noted a card rate cap “can only be done by Congress,” while Barclays said the president has “limited ability” to push it through alone. Reuters

Investors eye JPMorgan’s results closely for signs of strength in investment banking and markets, along with management’s take on credit quality amid persistently high borrowing costs. New details on card balances and charge-offs could carry extra weight now that Washington has reentered the pricing debate.

The downside risk is clear this morning. If inflation comes in hotter than expected, yields could spike, undermining the rate-cut story that’s been supporting bank shares and the wider rally.

The next major event is the U.S. Consumer Price Index report, a key measure of household inflation, set for release at 1330 GMT (8:30 a.m. ET). Traders will focus on that data initially, then shift attention to the earnings and outlook from the first major banks reporting this quarter.

Stock Market Today

  • Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK
    May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines and capital strategies amid challenging market conditions.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 01.05.2026

1 May 2026
LIVEMarkets rolling coverageStarted: May 1, 2026, 12:00 AM EDTUpdated: May 1, 2026, 12:15 AM EDT Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines
Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
Alibaba stock price today: BABA in focus after 10% jump on China “AI+ Manufacturing” push
Previous Story

Alibaba stock price today: BABA in focus after 10% jump on China “AI+ Manufacturing” push

Coinbase stock rises as Senate revives CLARITY Act crypto bill — stablecoin rewards in play
Next Story

Coinbase stock rises as Senate revives CLARITY Act crypto bill — stablecoin rewards in play

Go toTop